Peptomyc, member of CataloniaBio & HealthTech, announced today that it has received a €5 million grant from the EIC (European Innovation Council) acceleration program of Horizon Europe. This funding will allow Peptomyc to carry out a phase 1b clinical trial with its drug candidate OMO-103 in patients, as well as scale up its manufacturing process.
OMO-103 is a revolutionary therapy based on Peptomyc's PepBridge technology, which aims to inhibit cancer growth by regulating the Myc oncoprotein. This protein is overexpressed in various types of cancer and is a key factor in tumour proliferation. The development of OMO-103 aims to offer patients a more effective treatment option with fewer side effects than current conventional therapies.
The phase 1b clinical trial will allow Peptomyc to evaluate the efficacy and safety of OMO-103 in patients with certain types of cancer. This phase is crucial in determining the optimal dose and effects of the treatment in a real clinical setting. At the same time, the funding received will also allow Peptomyc to scale up its manufacturing process to ensure efficient and large-scale production.
"We are very excited to receive this grant from the EIC acceleration program of Horizon Europe", said Dr. Laura Soucek, founder and CEO of Peptomyc. "This funding will allow us to advance the development of OMO-103 and bring us closer to our mission of providing innovative and effective therapy to cancer patients."
Comments